Program News
News and stories about members of the UNC Lineberger Cancer Immunology and Immunotherapy Research Program
-
Ferris elected as Vice President of the Society for Immunotherapy of Cancer (SITC)
Robert L. Ferris, MD, PhD, will begin his term as the organization’s vice president on January 1, 2027. SITC is the world’s leading professional society dedicated to advancing the science and application of cancer immunotherapy.
-
What is TIL therapy?
A new form of immunotherapy called tumor-infiltrating lymphocyte (TIL) therapy is offering hope to some patients with metastatic melanoma who have few remaining treatment options.
-
Engineering better cancer fighters: In conversation with Justin Milner
UNC Lineberger’s Justin Milner, PhD, has emerged in recent years as a young scientist to watch in the field of cancer immunology.
-
UNC researchers create more effective, less toxic immunotherapy to combat blood cancer
Gianpietro Dotti, MD, Paul Armistead, MD, PhD, and colleagues have created a new cellular immunotherapy that targets acute myeloid leukemia (AML) cells without impacting normal blood production, which is one of the major challenges associated with AML treatment.